Slingshot members are tracking this event:

FDA Grants Priority Review for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer - PDUFA set for Aug. 2, 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Opdivo, Nivolumab, Pdufa, Dmmr, Msi-h Metastatic Colorectal Cance, Colorectal Cancer